Christoph Bausch - Mar 16, 2022 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Chief Science Officer
Signature
/s/ Christoph Lawrence Bausch
Stock symbol
SABS
Transactions as of
Mar 16, 2022
Transactions value $
$0
Form type
4
Date filed
3/18/2022, 09:15 PM
Previous filing
Oct 22, 2021
Next filing
Sep 15, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Employee Stock Option (right to buy) Award $0 +25K $0.00 25K Mar 16, 2022 Common Stock 25K $1.78 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.
F2 The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.